💉 GLP‑1 Receptor Agonists (Ozempic, Mounjaro & More): The Game‑Changers in Diabetes Care

If you’ve been reading about diabetes or weight loss lately, you’ve probably heard of Ozempic and Mounjaro. These belong to a class of injectable medications called GLP‑1 receptor agonists (and related dual agonists). They have transformed the treatment of Type 2 diabetes and obesity by lowering blood sugar, promoting significant weight loss, and protecting the heart and kidneys. Dr. Ravi Sishir Reddy explains exactly how these powerful drugs work, the different types available, and what you need to know before considering them.

1. What Are GLP‑1 Receptor Agonists?

GLP‑1 (glucagon‑like peptide‑1) is a natural incretin hormone released from the gut after eating. It helps control blood sugar in several ways: it tells the pancreas to release the right amount of insulin, reduces glucagon secretion (which stops the liver from overproducing glucose), and slows down stomach emptying so you feel fuller for longer. However, natural GLP‑1 is broken down by the DPP‑4 enzyme within minutes. GLP‑1 receptor agonists are synthetic versions that are resistant to this breakdown, providing a much longer and stronger effect.

These drugs not only lower blood sugar effectively but also reduce appetite and promote weight loss — often significant amounts. Some have been shown to reduce heart attacks and strokes in high‑risk individuals.

2. Which Drugs Are in This Class?

There are several GLP‑1 receptor agonists, differing mainly in how often they are taken (daily vs. weekly) and their potency for weight loss. Key examples include:

• Semaglutide (Ozempic, Wegovy): A once‑weekly injection. Ozempic is approved for Type 2 diabetes; Wegovy is a higher‑dose version for weight loss. It is highly effective, with typical weight loss of 5‑10% or more.
• Liraglutide (Victoza, Saxenda): A once‑daily injection. Victoza treats diabetes; Saxenda is for weight loss. It is slightly less potent for weight loss than semaglutide but still very effective.
• Dulaglutide (Trulicity): A once‑weekly injection, convenient single‑dose pen. Good cardiovascular protection proven in trials.
• Tirzepatide (Mounjaro): Technically a dual GIP/GLP‑1 receptor agonist — it mimics both GLP‑1 and GIP (glucose‑dependent insulinotropic polypeptide). This dual action provides even greater glucose lowering and weight loss (often 10‑15% of body weight). It is once‑weekly.
• Exenatide (Byetta, Bydureon): The original GLP‑1 agonist; Byetta is twice‑daily, Bydureon is once‑weekly.
• Lixisenatide (Lyxumia): Once‑daily, shorter‑acting.

All are given by subcutaneous injection (just under the skin) using a pen device, which is simple and nearly painless. Oral semaglutide (Rybelsus) is also available, a daily tablet formulation.

3. How Do GLP‑1 Agonists Lower Blood Sugar and Weight?

• Glucose‑dependent insulin secretion: They stimulate the pancreas to release insulin, but only when blood sugar is high — so they rarely cause hypoglycemia on their own.
• Glucagon suppression: They lower glucagon levels, reducing the liver’s glucose output, especially after meals.
• Slowed gastric emptying: Food leaves the stomach more slowly, which flattens the post‑meal glucose spike and increases satiety.
• Appetite suppression: They act on the brain’s appetite centres to reduce hunger and cravings, leading to reduced calorie intake and weight loss.

4. Proven Benefits: Weight Loss, Heart & Kidney Protection

• Weight loss: This is the standout benefit. Semaglutide and tirzepatide can achieve an average weight loss of 10‑15% of body weight, rivaling older weight‑loss drugs and even approaching bariatric surgery results in some individuals.
• Cardiovascular protection: Liraglutide, semaglutide, and dulaglutide have been shown in large trials to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in people with Type 2 diabetes and established heart disease or high risk.
• Kidney protection: These drugs reduce albuminuria (protein in the urine) and may slow the progression of diabetic kidney disease.
• Blood pressure reduction: A modest decrease in systolic BP (2‑5 mmHg) is commonly seen, partly due to weight loss.
• Improvement in fatty liver (NAFLD): Weight loss and improved insulin sensitivity help reduce liver fat and inflammation.

5. Common and Important Side Effects

• Gastrointestinal (GI) issues: Nausea, vomiting, diarrhoea, and constipation are the most common side effects, affecting up to 20‑40% of users. These are usually mild to moderate and improve over time. Starting with a low dose and gradually increasing (titration) helps reduce GI symptoms.
• Gallbladder problems: There is a slightly increased risk of gallstones and gallbladder inflammation (cholecystitis), likely related to rapid weight loss.
• Pancreatitis: Rare but has been reported. Severe abdominal pain should be evaluated immediately.
• Thyroid C‑cell tumours: In rodent studies, GLP‑1 agonists caused thyroid C‑cell tumours. It is unknown if this risk exists in humans, but as a precaution, these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2 syndrome (Multiple Endocrine Neoplasia type 2).
• Injection site reactions: Mild redness or itching at the injection site, usually temporary.

6. Who Should NOT Take GLP‑1 Agonists?

• Personal or family history of medullary thyroid cancer or MEN 2 syndrome.
• Pregnancy and breastfeeding: They are generally discontinued; insulin is preferred.
• Severe gastroparesis (delayed stomach emptying) — these drugs further slow gastric emptying.
• Type 1 diabetes: They are not approved for Type 1, although there is some research; risk of DKA may be increased.
• History of pancreatitis: Caution advised; some guidelines suggest avoiding them.

7. Practical Tips When Using a GLP‑1 Agonist

• Start low, go slow: Your doctor will start with the lowest dose and increase it gradually over weeks to minimise nausea. Do not rush the titration.
• Inject once weekly (most) or once daily: Follow the prescribed schedule. Use the pen device as demonstrated by your healthcare provider. Rotate injection sites (abdomen, thigh, upper arm) to avoid skin lumps.
• Take with or without food: Meal timing does not affect the drug, but if you are on insulin, you may need to adjust your mealtime dose.
• Stay hydrated: If you experience vomiting or diarrhoea, increase fluid intake to prevent dehydration.
• Monitor your blood sugar: Especially if you are also on insulin or sulfonylureas, as the dose may need to be reduced to avoid hypoglycemia.
• Report severe abdominal pain, persistent vomiting, or a lump in the neck: These could signal pancreatitis, severe gastroparesis, or a thyroid nodule.
• Plan for pregnancy: Stop the drug at least 2 months before trying to conceive, as advised by your doctor.